- In April 2024, Hamilton Thorne Ltd. (U.S.), a leader in precision laser and imaging systems for the fertility sector, announced the launch of its next-generation automated sperm analysis and separation system, ZyMōt X2. The advanced device enhances the separation of motile sperm with higher DNA integrity, supporting improved outcomes in assisted reproductive technologies (ART). This launch reinforces Hamilton Thorne’s commitment to innovation in reproductive health
- In March 2024, Memphasys Ltd. (Australia) received regulatory approval in India for its flagship sperm separation device, Felix. The device uses electrophoresis and size-exclusion membranes to select high-quality sperm non-invasively. The approval opens a large potential market, enhancing fertility treatment options in one of the world’s fastest-growing ART markets
- In February 2024, CooperSurgical Inc. (U.S.) expanded its ART portfolio by acquiring several new patents related to microfluidic sperm sorting technologies. These developments aim to improve the efficiency and safety of sperm preparation, particularly for use in intrauterine insemination (IUI) and in vitro fertilization (IVF)
- In January 2024, SAR Healthline Pvt Ltd. (India) introduced a cost-effective, single-use sperm separation kit for emerging markets. Designed for small to mid-sized fertility clinics, this launch aligns with the company's goal to improve access to fertility treatments across underserved regions in Asia and Africa
- In December 2023, Nidacon International AB (Sweden) partnered with leading fertility clinics in Europe to pilot its AI-integrated sperm selection platform. The system utilizes machine learning to analyze motility patterns and morphology in real-time, significantly boosting the accuracy of sperm separation processes and clinical outcomes
- In November 2023, Bonraybio (India) announced the development of a novel sperm preparation medium specifically tailored for high-viscosity semen samples. This innovation addresses a major challenge in male infertility treatments and has been well-received by embryologists in both domestic and Southeast Asian markets
